Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

121. Chlorpromazine versus reserpine for schizophrenia. (PubMed)

Chlorpromazine versus reserpine for schizophrenia. In the 1940s reserpine, refined from a plant extract that had been used for centuries, began to be used as a treatment for people with mental disorders and was one of the very first antipsychotic drugs. Its irreversible pharmacological potency and adverse effects meant that it has been withdrawn in the UK and its role has been superceded by 'newer' compounds. The effects of reserpine are of historical interest although there are some reports (...) of it still being used in highly specialist situations in psychiatry. Chlorpromazine is also an old drug but it is still used for treatment of people with schizophrenia.To investigate the effects of two old medications (reserpine and chlorpromazine) for people with schizophrenia. Reserpine is now rarely used while chlorpromazine remains on the essential list of drugs of the World Health Organization (WHO).We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (24 March 2016).We

2016 Cochrane

122. Risperidone (depot) for schizophrenia. (PubMed)

Risperidone (depot) for schizophrenia. Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation.To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication.To critically appraise and summarise current evidence on the resource use, cost and cost-effectiveness of risperidone (depot) for schizophrenia.We searched the Cochrane (...) Schizophrenia Group's Register (December 2002, 2012, and October 28, 2015). We also checked the references of all included studies, and contacted industry and authors of included studies.Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia-like psychoses.Two review authors independently selected trials, assessed trial quality and extracted data. For dichotomous data, we calculated the risk ratio (RR), with 95% confidence interval (CI

Full Text available with Trip Pro

2016 Cochrane

123. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. (PubMed)

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Chlorpromazine is an aliphatic phenothiazine, which is one of the widely-used typical antipsychotic drugs. Chlorpromazine is reliable for its efficacy and one of the most tested first generation antipsychotic drugs. It has been used as a 'gold standard' to compare the efficacy of older and newer antipsychotic drugs. Expensive new generation drugs are heavily marketed worldwide as a better treatment for schizophrenia (...) , but this may not be the case and an unnecessary drain on very limited resources.To compare the effects of chlorpromazine with atypical or second generation antipsychotic drugs, for the treatment of people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register up to 23 September 2013.We included randomised controlled trials (RCTs) that compared chlorpromazine with any other atypical antipsychotic drugs for treating people with schizophrenia. Adults (as defined in each trial

Full Text available with Trip Pro

2016 Cochrane

124. Dietary advice for people with schizophrenia. (PubMed)

Dietary advice for people with schizophrenia. People with serious mental illness have consistently higher levels of mortality and morbidity than the general population. They have greater levels of cardiovascular disease, metabolic disease, diabetes, and respiratory illness. Although genetics may have a role in the physical health problems of these people, lifestyle and environmental factors such as smoking, obesity, poor diet, and low levels of physical activity play a prominent part.To review (...) the effects of dietary advice for schizophrenia and schizophrenia-like psychosis.We searched the Cochrane Schizophrenia Group's Trials Register (September 09, 2013 and February 24, 2016).We planned to include all randomised clinical trials focusing on dietary advice versus standard care.The review authors (RP, KTP) independently screened search results but did not identify any studies that fulfilled the review's criteria.We did not identify any studies that met our inclusion criteria.Dietary advice has

Full Text available with Trip Pro

2016 Cochrane

125. Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. (PubMed)

Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. To determine whether refugees are at elevated risk of schizophrenia and other non-affective psychotic disorders, relative to non-refugee migrants from similar regions of origin and the Swedish-born population.Cohort study of people living in Sweden, born after 1 January 1984 and followed from their 14th birthday or arrival in Sweden, if later, until diagnosis of a non (...) sub-Saharan Africa had similarly high rates relative to the Swedish-born population.Refugees face an increased risk of schizophrenia and other non-affective psychotic disorders compared with non-refugee migrants from similar regions of origin and the native-born Swedish population. Clinicians and health service planners in refugee receiving countries should be aware of a raised risk of psychosis in addition to other mental and physical health inequalities experienced by refugees.Published

Full Text available with Trip Pro

2016 BMJ

126. Understanding causes of and developing effective interventions for schizophrenia and other psychoses

Understanding causes of and developing effective interventions for schizophrenia and other psychoses Understanding causes of and developing effective interventions for schizophrenia and other psychoses Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

Full Text available with Trip Pro

2016 NIHR HTA programme

127. [Scale for assessing negative symptoms in schizophrenia: A systematic review]. (PubMed)

[Scale for assessing negative symptoms in schizophrenia: A systematic review]. Negative symptoms are a fundamental dimension of schizophrenia despite their limited role in the international diagnostic classification. Although a consensual definition seems to be attempted regarding the main negative dimensions (anhedonia, alogia, social withdrawal, blunted affect, avolition), several standardized assessment scales have been created.The objective of this study was to identify a set (...) of unidimensional instruments which allows an assessment of negative symptoms in schizophrenia and also to identify their general characteristics and the items included.Inclusion criteria were: (a) the unidimensional assessment scales of negative symptoms of schizophrenia; (b) instruments in English (with French versions if possible); (c) all assessment instruments, the oldest and the most recent. The investigation ended in February 2013.Twelve unidimensional instruments were identified with only one of them

2016 L'Encephale

128. Social cognition interventions for persons with schizophrenia: evidence and clinical practice guidelines. (PubMed)

Social cognition interventions for persons with schizophrenia: evidence and clinical practice guidelines. Although most of the research conducted up to now has shown that interventions in social cognition are effective in the rehabilitation of persons with schizophrenia, there are still no clinical practice recommendations on the topic. Their development could facilitate the clinical work, resource management and the care provided to persons with such a disorder. This article addresses (...) this need and performs a systematic review of the identified high-quality scientific evidence and develops clinical practice recommendations. A total of 40 clinical trials and 1 meta-analysis evaluating the effects of social cognition interventions for persons with schizophrenia were selected for the present study. Taking into account the evidence available and its quality, the authors developed three clinical practice recommendations on the positive effects of these interventions. The analysis

2016 Actas españolas de psiquiatría

129. Antioxidant treatments for schizophrenia. (PubMed)

Antioxidant treatments for schizophrenia. There is accumulating evidence that progressive changes in brain structure and function take place as schizophrenia unfolds. Among many possible candidates, oxidative stress may be one of the mediators of neuroprogression, grey matter loss and subsequent cognitive and functional impairment. Antioxidants are exogenous or endogenous molecules that mitigate any form of oxidative stress or its consequences. They may act from directly scavenging free (...) radicals to increasing anti-oxidative defences. There is evidence that current treatments impact oxidative pathways and may to some extent reverse pro-oxidative states in schizophrenia. The existing literature, however, indicates that these treatments do not fully restore the deficits in antioxidant levels or restore levels of oxidants in schizophrenia. As such, there has been interest in developing interventions aimed at restoring this oxidative balance beyond the benefits of antipsychotics

Full Text available with Trip Pro

2016 Cochrane

130. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study (PubMed)

Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study Although mortality related to psychotropic medications has received much attention in recent years, little is known about the relationship between risk of death and cumulative antipsychotic load, and even less about the relationship between mortality and cumulative exposure to antidepressants or benzodiazepines. The authors examined (...) these relationships using nationwide databases.The authors used prospectively collected nationwide databases to identify all individuals 16-65 years of age with a schizophrenia diagnosis (N=21,492) in Sweden. All-cause and cause-specific mortality rates were calculated as a function of cumulative low, moderate, and high exposure to antipsychotics, antidepressants, and benzodiazepines from 2006 through 2010.Compared with no exposure, both moderate (adjusted hazard ratio=0.59, 95% CI=0.49-0.70) and high (adjusted

Full Text available with Trip Pro

2016 EvidenceUpdates

131. Schizophrenia. (PubMed)

Schizophrenia. Schizophrenia is a complex, heterogeneous behavioural and cognitive syndrome that seems to originate from disruption of brain development caused by genetic or environmental factors, or both. Dysfunction of dopaminergic neurotransmission contributes to the genesis of psychotic symptoms, but evidence also points to a widespread and variable involvement of other brain areas and circuits. Disturbances of synaptic function might underlie abnormalities of neuronal connectivity

Full Text available with Trip Pro

2016 Lancet

132. Origin and schizophrenia in young refugees and inter-country adoptees from Latin America and East Africa in Sweden: a comparative study (PubMed)

Origin and schizophrenia in young refugees and inter-country adoptees from Latin America and East Africa in Sweden: a comparative study Migrants' socioeconomic adversity has been linked to schizophrenia.To investigate whether the more favourable socioeconomic situation of adoptees prevents them from the high risk of schizophrenia found in other migrants.Register study in a cohort of refugees and inter-country adoptees aged 16-40 years, born in East Africa (n=8389), Latin America (n=11 572 (...) ) and 1.2 million native Swedes. Cox-regression models estimated hazard ratios (HRs) of schizophrenia in data from psychiatric care.Despite diverse income levels, HRs for schizophrenia were similar for refugees and adoptees, with East Africans having the highest HRs: 5.83 (3.30-10.27) and 5.80 (5.03-6.70), followed by Latin Americans: HRs 3.09 (2.49-3.83) and 2.31 (1.79-2.97), compared with native Swedes. Adjustment for income decreased these risks slightly for refugees, but not for adoptees.This study

Full Text available with Trip Pro

2016 BJPsych open

133. Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?

Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Article Text Further commentaries Electronic pages

2016 Evidence-Based Mental Health

134. Pharmacological interventions: Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?

Pharmacological interventions: Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Article Text Electronic pages Pharmacological interventions Which

2016 Evidence-Based Mental Health

135. Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders

Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Article Text Causes and risk

Full Text available with Trip Pro

2016 Evidence-Based Mental Health

136. Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis

Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Article Text Pharmacological interventions Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Taro Kishi Statistics from Altmetric.com ABSTRACT FROM: Samara MT, Leucht C, Leeflang MM, et al . Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J

2016 Evidence-Based Mental Health

137. Alpha-7 nicotinic agonist improves cognition in schizophrenia

Alpha-7 nicotinic agonist improves cognition in schizophrenia Alpha-7 nicotinic agonist improves cognition in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Alpha-7 nicotinic agonist improves cognition in schizophrenia Article Text Pharmacological interventions Alpha-7 nicotinic agonist improves cognition in schizophrenia Stephen R. Marder Statistics from Altmetric.com ABSTRACT FROM: Keefe RS, Meltzer HA, Dgetluck N

2016 Evidence-Based Mental Health

138. Vitamin D in schizophrenia: a clinical review

Vitamin D in schizophrenia: a clinical review Vitamin D in schizophrenia: a clinical review | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin D in schizophrenia: a clinical review Article Text Clinical review Vitamin D in schizophrenia: a clinical review Mathew Chiang , Radhika Natarajan , Xiaoduo Fan , Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which

2016 Evidence-Based Mental Health

139. Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia

Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Article Text Psychological interventions Targeting social and non-social cognition

2016 Evidence-Based Mental Health

140. Measures to support positive lifestyle changes in people with schizophrenia

Measures to support positive lifestyle changes in people with schizophrenia 1 Measures to support positive lifestyle changes in people with schizophrenia sbu report | a systematic review of the scientific evidence 2014 | www.sbu.se/232 Summary Schizophrenia is a chronic, debilitating mental dis- order. On average, life expectancy is 15 years shorter for men and 12 years shorter for women than for the rest of the population. Factors such as smoking, alco- hol/drug abuse, inadequate diet and lack (...) of physical activity contribute to a high degree of coexisting conditions, such as type 2 diabetes and cardiovascular diseases. SBU’s assessment of the state of knowledge • A combination of behavioural measures to pro- mote physical activity and healthy eating habits yields only a minor decrease in body weight and BMI, and a minor improvement in quality of life for persons with schizophrenia. There are no stu - dies to determine whether this effect persists for more than twelve months. It is unclear

2016 Swedish Council on Technology Assessement